text: CPT requires specialized chimeric probes, making CPT assays more expensive than PCR. Because CPT probes are so specific, a new probe must be designed for each unique assay, further increasing cost. Clinical implementation is hampered financially, but it is also limited by the possibility of samples containing nonspecific RNases other than RNase H.